5 recruiting, 4 completed, 2 active not recruiting, 2 not yet recruiting. 8 Phase 2, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Completed 2, Recruiting 2, Not yet recruiting 1, Unknown 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Rectal Cancer Stage II: new trials by email Literature Review of Rectal Cancer Stage II trials Research Report on Rectal Cancer Stage II
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial Time-restricted eating, Questionnaire Administration, Biospecimen Collection - Rectal Cancer Stage II, Rectal Cancer Stage III | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 100 | 2026-07-23 | 2026-07-29 |
| Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group, mFOLFOX regimen neoadjuvant therapy group - Rectal Cancer Patients, Rectal Cancer Stage II | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 236 | 2026-03-20 | 2026-05-26 |
| Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy - Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II | Phase 2 | Not yet recruiting | Beijing Friendship Hospital | 19 | 2026-03-01 | 2026-02-11 |
| Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer Total mesorectal excision, Neoadjuvant Chemotherapy followed by total mesorectal excision - Mid-Rectal Cancer, Rectal Cancer Stage II | Not yet recruiting | Turkish Society of Colon and Rectal Surgery | 436 | 2025-08-01 | 2025-06-27 | |
| The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial Prehabilitation Program - Rectal Cancer, Colorectal Cancer | Not applicable | Recruiting | Dana-Farber Cancer Institute | 40 | 2024-12-15 | 2026-09-30 |
| ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer Rectal Cancer, Rectal Cancer Stage II | Recruiting | Gene Solutions | 100 | 2024-05-21 | 2024-09-19 | |
| The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer Tislelizumab combined with chemotherapy - Rectal Cancer, Rectal Cancer Stage II | Phase 2 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 60 | 2024-02-22 | 2024-02-12 |
| "Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study". neoadjuvant treatment - Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II | Completed | Hospital San Carlos, Madrid | 4 | 2021-09-01 | 2022-08-10 | |
| Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy - Rectal Cancer Stage II, Rectal Cancer Stage III | Phase 2 | Active not recruiting | Jules Bordet Institute | 72 | 2021-03-25 | 2026-05-22 |
| Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer MRI, blood routine test - Rectal Cancer Stage II, Rectal Cancer Stage III | Unknown | Peking University Third Hospital | 120 | 2021-02-01 | 2021-07-21 | |
| TNT to Increase the Clinical Complete Response Rate for Distal LARC Capecitabine, Oxaliplatin, External beam radiotherapy, Surgery - Rectal Cancer, Rectal Cancer Stage II | Phase 2 | Active not recruiting | Sun Yat-sen University | 98 | 2018-12-25 | 2023-10-25 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. Radiotherapy, Chemotherapy, Deep regional hyperthermia - Rectal Cancer, Rectal Neoplasms | Phase 2 | Unknown | University Hospital Tuebingen | 94 | 2018-06-15 | 2018-06-19 |
| Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer Induction Chemotherapy arm A, Radiation arm A, Radiation arm B - Rectal Neoplasms, Rectal Cancer Stage II | Phase 2 | Completed | Prof. Dr. med. Claus Rödel | 311 | 2015-03-25 | 2023-12-04 |
| Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma total mesorectal excision / long course radiochemotherapy, long course 5-FU bases radiochemotherapy - Rectal Cancer Stage II, Rectal Cancer Stage III | Completed | Johannes Gutenberg University Mainz | 1051 | 2009-02-01 | 2016-10-19 |
Rectal Neoplasms (15) · Breast Neoplasms (2) · Bile Duct Neoplasms (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Intermittent Fasting (1) · Laryngeal Neoplasms (1) · Lip Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Mouth Neoplasms (1)
Digestive System Diseases (15) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Gastrointestinal Neoplasms (15) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Neoplasms (15) · Neoplasms by Site (15) · Rectal Diseases (15) · Colorectal Neoplasms (14) · Breast Diseases (2) · Colonic Diseases (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Drug Therapy (3) · Surgical Procedures, Operative (3) · Fluorouracil (2) · Radiotherapy (2) · Immunotherapy (1) · Neoadjuvant Therapy (1) · Nivolumab (1) · Oxaliplatin (1) · Tablets (1) · XELOX (1) · regorafenib (1)
Beijing Friendship Hospital (1) · Dana-Farber Cancer Institute (1) · First Affiliated Hospital of Guangxi Medical University (1) · Fred Hutchinson Cancer Center (1) · Gene Solutions (1) · Hospital San Carlos, Madrid (1) · Johannes Gutenberg University Mainz (1) · Jules Bordet Institute (1) · Klus Pharma Inc. (1) · Peking University Third Hospital (1) · Prof. Dr. med. Claus Rödel (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-sen University (1) · Turkish Society of Colon and Rectal Surgery (1) · University Hospital Tuebingen (1)
China (5) · Germany (3) · United States (3) · Belgium (1) · Spain (1) · Turkey (Türkiye) (1) · Vietnam (1)
Aras Emre Canda, Prof. (1) · Cigdem N Arslan, Prof. (1) · Cihan Gani, Dr. (1) · Feza Karakayali, Prof. (1) · Francesco Sclafani, MD (1) · Hui Li, Professor (1) · Ilknur Erenler Bayraktar, Prof. (1) · Jane Figueiredo, PhD, M.Sc. (1) · Jeffrey Meyerhardt, MD, MPH (1) · Jordi Rodon Ahnert, MD, PhD (1) · Ning Lang, Professor (1) · Onur Bayraktar, Prof. (1) · Sinh D Nguyen, PhD (1) · Tayfun Bisgin, Prof. (1)
PMID 26223668, PMID 26556476, PMID 32697965, PMID 34792531, PMID 36572280, PMID 37335957, PMID 40347958, PMID 41191581, PMID 42318526
P50CA285275 (1)